Neurofibroma differential diagnosis

Neurofibroma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neurofibroma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neurofibroma differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neurofibroma differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neurofibroma differential diagnosis
CDC on Neurofibroma differential diagnosis
Neurofibroma differential diagnosis in the news
Blogs on Neurofibroma differential diagnosis
Directions to Hospitals Treating Neurofibroma
Risk calculators and risk factors for Neurofibroma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]

Overview

Neurofibroma must be differentiated from schwannoma, dermatofibrosarcoma protuberans (DFSP), ganglioneuroma, and melanocytic nevus.

Differential Diagnosis

Neurofibroma must be differentiated from:

• Schwannoma
• Dermatofibrosarcoma protuberans (DFSP)
• Ganglioneuroma
• Melanocytic nevus
• Myxoid liposarcoma
• Solitary circumscribed neuroma (palisaded encapsulated neuroma)
• Traumatic neuroma
• Neurotized nevus
• Superficial angiomyxoma
• Nerve sheath myxoma
• Malignant peripheral nerve sheath tumor (MPNST): has marked atypia and increased mitotic activity, may have necrosis
• Spindle cell lipoma
• Leiomyoma: has cigar-shaped nuclei, S100 negative, positive for smooth muscle actin and desmin
• Inflammatory myofibroblastic tumor: reactive spindle cells in inflammatory background

Differentiating neurofibroma from other diseases

Disease entity	Etiology (Genetic or other)	Histopathological findings	Immunohistochemical staining	Benign/Malignant	Risk factors	Common site of involvement	Clinical manifestations	Other associated features
Neurofibroma		Uniphasic, low to moderate cellularity Non-encapsulated Random pattern, only rare palisading No well formed verocy bodies Cells separated by collagen bundles Hypocellular with abundant mucinous matrix No peripheral perineural capsule Frequent mast cells Contains neural fibroblasts and fibrillary collagen Random proliferation of Schwann cells and scattered admixed axons No nevoid cells No epithelial component Diffuse growth pattern Scant cytoplasm Wavy cells with buckled nuclei Pseudomeissnerian bodies representing specific differentiation may be present Lacks storiform pattern Neurofibroma with degenerative atypia ("ancient change") has following microscopic features: Localized cells with large pleomorphic nuclei, cytoplasmic nuclear inclusions, smudgy chromatin, and inconspicuous nuclei Absent or very low mitotic activity Low to moderate cellularity	Positive for: S100 GFAP CD34		NF-1 associated	Can occur anywhere		Nerve often not identified, incorporates nerve, axons often present in lesion Seldom cystic Frequently multiple Widespread soft tissue infiltration Tends to displace adnexa <2cm in diameter Lacks distinct lobulation Lacks fat
Schwannoma
Palisaded encapsulated neuroma
Traumatic neuroma
Neurotized Melanocytic Nevus
Cutaneous Myxoma (Superficial angiomyxoma)
Nerve sheath myxoma
Malignant peripheral nerve sheath tumor
Dermatofibrosarcoma protuberans (DFSP)
Spindle cell lipoma

References

Template:WikiDoc Sources